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Abstract
Background: The risk of contrast-induced acute kidney injury (CI-AKI) increases in a nonlinear
fashion with increasing volume of contrast media. Prior studies recommend limiting contrast
volume to less than three times the estimated creatinine clearance (CC). Recently, a number of
operators have reported successful percutaneous coronary intervention (PCI) using even lower
volumes of contrast.
Objectives: To evaluate the prevalence and outcomes associated with ultra-low contrast volume
among patients undergoing PCI.
Methods: We assessed the prevalence and outcomes associated with use of ultra-low contrast
volume among 75 393 patients undergoing PCI in Michigan between July 2014 and June 2017
in the BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) registry. Ultra-low
contrast volume was defined as contrast volume less than or equal to the patient's estimated
CC. Patients receiving dialysis at the time of the procedure were excluded.
Results: Ultra-low contrast volume was used in 13% of procedures with the majority of these
patients being at low risk of renal complications. Compared with patients who received a contrast
volume between one and three times the CC, use of ultra-low volume of contrast was associated
with a significantly lower incidence of AKI (aOR 0.682, 95% CI 0.566–0.821, P < 0.001) and a
lower incidence of need for dialysis (aOR = 0.341, 95% CI 0.165–0.704, P = 0.003). These bene-
fits were most evident in the patients with a high baseline predicted risk of AKI.
Conclusions: A small but clinically significant number of patients are treated with ultra-low con-
trast volume. Ultra-low contrast volume use is associated with a significant reduction in the inci-
dence of AKI or need for dialysis. It may be prudent to consider this new threshold when
performing PCI on patients who are at an increased risk of AKI.
KEYWORDS
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1 | INTRODUCTION
Contrast-induced acute kidney injury (CI-AKI) is a common complica-
tion of invasive cardiac procedures and is associated with increased
morbidity, mortality, and health care cost 1,2. Use of low-osmolar or
iso-osmolar contrast media, contrast volume minimization, and appro-
priate hydration are the only evidence-based strategies that have
been effective at reducing the incidence of CI-AKI 3,4. Current profes-
sional society recommendations focus on identification of high-risk
patients, appropriate peri-procedural hydration and minimization of
contrast volume in high-risk patients as strategies to prevent CI-AKI 5.
Abbreviations: PCI, percutaneous coronary intervention; CC, creatinine clear-
ance; CI-AKI, contrast-induced acute kidney injury
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In previous work, our group and others have suggested a benefit of
renal function-based contrast media dosing with a contrast dose of
less than three times the estimated creatinine clearance (CC) being
associated with a low incidence of CI-AKI 6,7.
The increasing awareness of the association of contrast media
volume with the risk of CI-AKI appears to have resulted in a change in
practice toward using lower doses of contrast media for all patients 8 .
In addition, select centers have reported their experience with per-
forming percutaneous coronary intervention (PCI) with ultra-low vol-
ume of contrast media, especially in high-risk patients 9,10.
The prevalence and clinical impact of this practice in the broader
interventional community remains unknown. Our study had two aims.
First, we sought to identify the prevalence of ultra-low contrast use in
a broad and unselected population of patients undergoing PCI in
Michigan using the BMC2 (Blue Cross Blue Shield of Michigan Cardio-
vascular Consortium) registry, a large multicenter quality improvement
collaborative. Second, we assessed the impact of ultra-low contrast
volume administration on reducing the risk of acute kidney injury
(AKI), and need for dialysis.
2 | MATERIALS AND METHODS
2.1 | Study population
Our study population was comprised all patients undergoing PCI
between July 1, 2014 and June 30, 2017 at every nonfederal hospital
in the state of Michigan and enrolled in the BMC2 registry. This regis-
try has been previously described in detail elsewhere 11,12. BMC2 is a
quality improvement collaborative of all nonfederal hospitals that per-
form PCI in the state of Michigan that works to facilitate inter institu-
tional quality improvement. A total of 47 hospitals participate in the
registry, of which 14 perform PCI without on-site cardiac surgery
backup. Procedural data on all patients undergoing PCI at participating
hospitals are collected using NCDR Cath PCI data collection system
with additional data elements collected using a BMC2 website. Base-
line data include clinical, demographic, procedural, and angiographic
characteristics, as well as pharmacotherapy used before, during, and
after the procedure, and in-hospital outcomes. All data elements are
prospectively defined, and a rigorous study coordinator training and
education program is in place to ensure high data quality. All study
sites are audited at least once a year by an experienced nurse auditor.
We excluded patients who were on dialysis at the time of the
procedure, those who died in the catheterization laboratory, those
undergoing salvage PCI, those who underwent coronary artery bypass
grafting during the same hospitalization, those missing preprocedural
or postprocedural creatinine values, and those in whom glomerular fil-
tration rate or baseline AKI risk could not be estimated due to missing
information.
We defined ultra-low contrast volume as a contrast dose less
than or equal to the calculated CC. In a previous modelling study, this
threshold appeared to be associated with a statistically lower adjusted
risk of renal complications 13. High contrast volume was defined as a
contrast dose less than three times CC. Low contrast volume was
defined as a contrast dose that was greater than the CC but less than
or equal to three times the CC.
2.2 | Study endpoints
This study had two end points, AKI and the new need for dialysis.
Acute kidney injury was defined as a post-PCI elevation in serum cre-
atinine of ≥0.5 mg/dL above the pre-PCI value. We and others have
previously demonstrated this definition to be preferable to more sen-
sitive definitions of AKI for predicting the likelihood of hard clinical
events 14,15.
Peak creatinine was defined as the highest value of creatinine in
the week after the procedure and was ascertained as per local clinical
practice. A follow-up creatinine was collected at least 1 day after the
procedure but varied, depending on length of stay. The CC was calcu-
lated with the Cockcroft–Gault Equation 16. Cockcroft–Gault equation
was used for assessment of renal function adjusted contrast dose as
this estimate has been conventionally used for renal dosing of medica-
tions, and has been used in previous work describing renal function
based contrast thresholds 6,17.
2.3 | Statistical analysis
Pearson chi-square tests were utilized for comparisons of categorical
variables, and Student t-tests for comparisons of continuous variables
between cases with CV/CC ≤ 1 (Ultra-low volume) and cases with
CV/CC between 1 and 3 (low volume). Preprocedural risk of AKI was
estimated using the BMC2 risk prediction model, which has been
described previously 18 and is implemented as an online calculator
(available for review at http://scaipciriskapp.org/pci_welcome).
Logistic regression models adjusting for estimated preprocedural
AKI risk were utilized to assess the impact of contrast volume indexed
to CC on AKI incidence. The extent to which the effect of contrast
volume varied by baseline AKI risk was assessed through the inclusion
of risk category (<1, 1–7, and >7% baseline predicted AKI risk) by
ultra-low contrast interaction terms, and the likelihood ratio test was
used to determine whether the addition of an estimated risk by ultra-
low contrast interaction term significantly improved the fit of the
model. The regression model was then utilized to determine number
needed to treat (NNT) adjusting for estimated preprocedural AKI risk.
Using the fitted model, two predicted AKI rates were obtained. First,
we predicted AKI rate if all patients in the study cohort received ultra-
low contrast volume (AKI rate a). We then predicted the AKI rate if all
patients were to have received low contrast volume (AKI rate b). NNT
was then estimated as the inverse of the difference of the two pre-
dicted rates (NNT = 1/[b − a]).
Logistic regression was utilized to determine patient baseline clin-
ical and demographic characteristics independently associated with
ultra-low contract use, with all variables having absolute standardized
differences between ultra-low contrast cases and either low or high
contrast volume use cases of 10% or greater evaluated as predictors,
variables having coefficients with Wald P values of alpha = 0.05 or
less were considered to be independent predictors. To determine the
extent that ultra-low contrast volume use varied between hospitals or
PCI operators after accounting for patient factors, a generalized linear
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mixed effect regression model was fitted adjusting for patient level
independent predictors as fixed effect terms, and including random
intercept terms for unique hospitals and operators. The median odds
ratio (MOR) statistics was estimated from this model, with a 95% con-
fidence interval obtained using a parametric bootstrap procedure iter-
atively drawing from the estimated posterior distributions of the
random effects 19. MOR estimates reflect the extent of intrasite and
intraoperator contribution to overall variance in the use of ultra-low
contrast volume. All analyses were performed using R version 3.4.1.
3 | RESULTS
A total of 91 945 patients underwent PCI during the 3 years of the
study period of whom 75 393 comprised our study population
(Supporting Information Figure S1). The average contrast volume was
171 mL with a median contrast volume of 160 mL (IQR 120–209 mL).
The distribution of CC adjusted contrast dose in the total cohort is
provided in Figure 1. Ultra-low contrast volume was used in 13% of
patients during this study period. The baseline characteristics of the
cohort categorized by CV/CC of ≤1 (ultra-low volume), CV/CC > 1–3
(low volume), and CV/CC > 3 (high volume) are provided in Table 1.
There were multiple statistically significant but clinically minor differ-
ences between those treated with ultra-low contrast volume com-
pared with those administered larger contrast dose. Compared with
patients treated with low contrast volume, those treated with ultra-
low contrast were more likely to be younger, taller, and of greater
body weight and more likely to be undergoing radial access and had a
lower serum creatinine at baseline. The calculated risk of AKI was
2.09% in those treated with ultra-low contrast volume compared with
2.62% in those treated with a low contrast volume.
The distribution of ultra-low volume contrast use among patients
at varying risk of AKI and by baseline renal function are provided in
Supporting Information Figure S2. The majority of patients who were
treated with ultra-low contrast volume were at low risk of AKI (60%
had a predicted risk of <1%).
The unadjusted and risk adjusted incidence of AKI in the entire
cohort categorized by CV/CC is provided in Figure 2. There was an
increase in the risk of AKI with increasing renal function adjusted con-
trast dose. When categorized by the predicted risk of AKI, the advan-
tage of ultra-low contrast volume was most evident in the highest-risk
cohort (Figure 3).
In a logistic regression model adjusting for estimated baseline risk
of AKI, ultra-low contrast volume was associated with a lower inci-
dence of AKI compared with those administered a low contrast vol-
ume (OR 0.682, 95% CI 0.566–0.821, P < 0.001). The addition of a
predicted risk by ultra-low contrast interaction term significantly
improved the fit of the regression model, with the effect of ultra-low
contrast increasing with greater baseline AKI risk. (LRT = 4.32 on 1 df,
P = 0.038). The NNT for avoiding one AKI event with use of ultra-low
contrast volume compared with a low dose was 410 for patients with
a predicted risk of AKI of <1% (low risk), 246 for intermediate risk
group, and 18 for the high-risk cohort (predicted risk > 7%).
In subsequent stratified analysis of cases where predicted AKI risk
was >7%, ultra-low contrast volume was associated with lower AKI
incidence after adjusting for baseline BMC2 estimated AKI risk
(OR = 0.673, 95% CI 0.511–0.887, P = 0.005).
The total number of patients who needed dialysis was low:
9/9857 (0.091%) in those treated with ultra-low volume contrast,
113/51584 (0.219%) in those receiving a low volume and 189/13952
(1.35%) in those administered a high volume (Chi-square P = 0.009
for ultra-low volume vs low volume, and P < 0.001 for ultra-low vs
high volume). After adjusting for the baseline predicted risk of dialysis,
the use of ultra-low volume contrast was a significantly associated
with lower odds of new need for dialysis (OR = 0.34, 95% CI
0.17–0.70, P = 0.003 for ultra-low volume vs low volume, and OR =
0.14, 95% CI 0.07–0.30, P < 0.001, for ultra-low volume vs high
volume).
There was significant difference in the use of ultra-low contrast
volume across the individual operators and the participating institu-
tions (Figure 4). The independent predictors of ultra-low volume con-
trast use are provided in Supporting Information Table S1. After
FIGURE 1 Distribution of PCI procedures by ratio of contrast volume to CC [Color figure can be viewed at wileyonlinelibrary.com]
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TABLE 1 Baseline characteristics, procedural variables, and key in-hospital outcomes of the cohort categorized by contrast volume to CC ratio
Contrast volume group
Ultra-low contrast
volume compared to
low contrast volume
Ultra-low contrast
volume compared to
high contrast volume
Characteristic
Ultra-low
(CV/CC ≤ 1) Low (CV/CC > 1–3) High (CV/CC > 3) P
Abs.
Std. diff P
Abs.
Std. diff
Demographic characteristics
Age (years) 57.49  10.85 64.93  11.21 74.38  10.46 <0.001 67.37 <0.001 158.5
Height (cm) 173.34  10.54 171.74  10.34 167.92  10.56 <0.001 15.34 <0.001 51.4
Weight (kg) 103.06  24.85 90.77  20.21 77.84  17.61 <0.001 54.23 <0.001 117.1
Sex: male 6872/9857 (69.7%) 35 653/51584
(69.1%)
8017/13952
(57.5%)
0.237 1.30 <0.001 25.7
Sex: female 2985/9857 (30.3%) 15 931/51584
(30.9%)
5935/13952
(42.5%)
0.237 1.30 <0.001 25.7
Race—white 8496/9857 (86.2%) 44 915/51584
(87.1%)
12 006/13952
(86.1%)
0.018 2.58 0.758 0.4
Race—black or African
American
1128/9857 (11.4%) 5530/51584
(10.7%)
1642/13952
(11.8%)
0.034 2.30 0.441 1.0
Race—Asian 102/9857 (1.0%) 582/51584 (1.1%) 175/13952 (1.3%) 0.418 0.90 0.120 2.1
Race—American Indian or
Alaskan native
46/9857 (0.5%) 176/51584 (0.3%) 33/13952 (0.2%) 0.057 1.98 0.002 3.9
Race—native Hawaiian or
Pacific islander
11/9857 (0.1%) 33/51584 (0.1%) 10/13952 (0.1%) 0.105 1.61 0.307 1.3
Hispanic or Latino
ethnicity
157/9815 (1.6%) 672/51303 (1.3%) 205/13889 (1.5%) 0.023 2.42 0.445 1.0
Admit source: emergency
department
4380/9846 (44.5%) 22 792/51537
(44.2%)
6111/13942
(43.8%)
0.633 0.52 0.317 1.3
Comorbidities, risk factors, and clinical presentation
Current/recent smoker
(w/in 1 year)
3734/9855 (37.9%) 14 970/51568
(29.0%)
2647/13948
(19.0%)
<0.001 18.86 <0.001 42.9
Hypertension 8181/9856 (83.0%) 43 480/51582
(84.3%)
12 534/13949
(89.9%)
0.001 3.48 <0.001 20.1
Dyslipidemia 7685/9849 (78.0%) 40 911/51553
(79.4%)
11 293/13947
(81.0%)
0.003 3.25 <0.001 7.3
Family history of
premature CAD
1709/9856 (17.3%) 6912/51577
(13.4%)
1228/13949 (8.8%) <0.001 10.94 <0.001 25.5
Prior MI 3485/9856 (35.4%) 17 464/51580
(33.9%)
4986/13951
(35.7%)
0.004 3.16 0.546 0.8
Prior heart failure 1403/9853 (14.2%) 8672/51579
(16.8%)
3550/13947
(25.5%)
<0.001 7.11 <0.001 28.4
Prior valve surgery/
procedure
115/9853 (1.2%) 932/51567 (1.8%) 452/13947 (3.2%) <0.001 5.29 <0.001 14.2
Prior PCI 4623/9857 (46.9%) 23 324/51579
(45.2%)
6302/13951
(45.2%)
0.002 3.37 0.008 3.5
Cerebrovascular disease 1056/9854 (10.7%) 7576/51582
(14.7%)
3101/13949
(22.2%)
<0.001 11.95 <0.001 31.4
Peripheral arterial disease 990/9854 (10.0%) 7090/51582
(13.7%)
2916/13951
(20.9%)
<0.001 11.44 <0.001 30.4
Chronic lung disease 1663/9855 (16.9%) 9769/51581
(18.9%)
3251/13948
(23.3%)
<0.001 5.39 <0.001 16.1
Diabetes mellitus 4229/9853 (42.9%) 19813/51576
(38.4%)
5436/13951
(39.0%)
<0.001 9.18 <0.001 8.1
CAD presentation: no
symptom, no angina
371/9855 (3.8%) 1536/51575 (3.0%) 410/13950 (2.9%) <0.001 4.36 <0.001 4.6
CAD presentation:
symptom unlikely to be
ischemic
221/9855 (2.2%) 1353/51575 (2.6%) 442/13950 (3.2%) 0.028 2.47 <0.001 5.7
CAD presentation: stable
angina
812/9855 (8.2%) 4782/51575 (9.3%) 1189/13950 (8.5%) 0.001 3.65 0.437 1.0
CAD presentation:
unstable angina
4305/9855 (43.7%) 22 089/51575
(42.8%)
5687/13950
(40.8%)
0.116 1.72 <0.001 5.9
2687/9855 (27.3%) <0.001 3.92 0.373 1.2
(Continues)
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TABLE 1 (Continued)
Contrast volume group
Ultra-low contrast
volume compared to
low contrast volume
Ultra-low contrast
volume compared to
high contrast volume
Characteristic
Ultra-low
(CV/CC ≤ 1) Low (CV/CC > 1–3) High (CV/CC > 3) P
Abs.
Std. diff P
Abs.
Std. diff
CAD presentation:
non-STEMI
13 171/51575
(25.5%)
3731/13950
(26.7%)
CAD presentation:
ST-elevation MI
(STEMI) or equivalent
1459/9855 (14.8%) 8644/51575
(16.8%)
2491/13950
(17.9%)
<0.001 5.37 <0.001 8.3
Heart failure w/in
2 weeks
1056/9849 (10.7%) 6364/51561
(12.3%)
2822/13943
(20.2%)
<0.001 5.08 <0.001 26.5
Cardiomyopathy or left
ventricular systolic
dysfunction
799/9854 (8.1%) 5042/51579 (9.8%) 2003/13944
(14.4%)
<0.001 5.84 <0.001 19.9
Preoperative evaluation
before noncardiac
surgery
149/9856 (1.5%) 867/51578 (1.7%) 262/13951 (1.9%) 0.228 1.35 0.033 2.8
Cardiogenic shock w/in
24 hr
93/9856 (0.9%) 731/51580 (1.4%) 509/13951 (3.6%) <0.001 4.39 <0.001 18.1
Cardiac arrest w/in 24 hr 124/9853 (1.3%) 980/51573 (1.9%) 365/13951 (2.6%) <0.001 5.15 <0.001 9.9
Procedural characteristics
Fluoroscopy time 11.27  8.36 15.67  11.61 23.44  17.74 <0.001 43.48 <0.001 87.8
Contrast volume 106.58  41.19 168.08  58.37 228.61  83.76 <0.001 121.73 <0.001 184.9
IABP 105/9857 (1.1%) 825/51575 (1.6%) 561/13952 (4.0%) <0.001 4.66 <0.001 18.9
Other mechanical
ventricular support
48/9857 (0.5%) 532/51569 (1.0%) 504/13951 (3.6%) <0.001 6.28 <0.001 22.2
Arterial access site:
femoral
4922/9857 (49.9%) 31 489/51579
(61.1%)
10 584/13952
(75.9%)
<0.001 22.51 <0.001 55.7
Arterial access site:
brachial
20/9857 (0.2%) 98/51579 (0.2%) 38/13952 (0.3%) 0.789 0.29 0.284 1.4
Arterial access site: radial 4908/9857 (49.8%) 19 946/51579
(38.7%)
3322/13952
(23.8%)
<0.001 22.53 <0.001 55.9
Arterial access site: other 7/9857 (0.1%) 46/51579 (0.1%) 8/13952 (0.1%) 0.574 0.64 0.679 0.5
PCI status: elective 2700/9857 (27.4%) 15 124/51584
(29.3%)
3900/13952
(28.0%)
<0.001 4.28 0.341 1.3
PCI status: urgent 5600/9857 (56.8%) 26 993/51584
(52.3%)
7249/13952
(52.0%)
<0.001 9.02 <0.001 9.8
PCI status: emergency 1557/9857 (15.8%) 9467/51584
(18.4%)
2803/13952
(20.1%)
<0.001 6.80 <0.001 11.2
Pre-PCI left ventricular
ejection fraction
52.98  11.92 51.87  12.94 49.44  14.56 <0.001 8.97 <0.001 26.6
Chronic total occlusion
PCI
150/9588 (1.6%) 1353/50563 (2.7%) 627/13637 (4.6%) <0.001 7.7 <0.001 17.6
Bifurcation PCI 495/9588 (5.2%) 3997/50563 (7.9%) 1565/13637
(11.5%)
<0.001 11.1 <0.001 23.0
Left main artery PCI 160/9588 (1.7%) 1428/50563 (2.8%) 863/13637 (6.3%) <0.001 7.8 <0.001 24.0
Atherectomy 106/9588 (1.1%) 993/50563 (2.0%) 496/13637 (3.6%) <0.001 7.0 <0.001 16.7
Cardiogenic shock at start
of PCI
97/9850 (1.0%) 782/51566 (1.5%) 556/13946 (4.0%) <0.001 4.79 <0.001 19.4
Laboratory values
Preprocedure creatinine 0.85  0.30 1.02  0.33 1.32  0.68 <0.001 52.72 <0.001 89.0
Preprocedure hemoglobin 13.76  1.89 13.58  1.92 12.75  2.05 <0.001 9.66 <0.001 51.5
Creatinine clearance
(Cockcroft–Gault)
143.1  54.7 95.3  34.7 56.5  22.0 <0.001 104.30 <0.001 207.50
Preprocedural estimated
AKI risk (%)
2.09  4.27 2.62  4.59 5.59  7.83 <0.001 12.11 <0.001 61.5
Key in-hospital outcomes
Dissection 47/9853 (0.5%) 368/51562 (0.7%) 207/13946 (1.5%) 0.0086 3.1 <0.0001 10.2
(Continues)
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adjusting for patient level factors, there was a large persistent difference
in the use of ultra-low contrast among the participating operators
(Supporting Information Figure 3) and the participating institutions
(Supporting Information Figure 4). The MOR for operators was 1.85
(1.78–1.92) and for institutions 1.62 (95%CI: 1.52–1.73) suggesting that
a similar patient was 1.85-fold more likely to receive ultra-low contrast
depending on the operator and 1.62-fold depending on the treating insti-
tution. By comparison, the model predicted odds ratio associated with a
10-point increase in patient GFR was 1.47, and for a 10-year decrease in
patient age was 1.49 (all else held constant), suggesting that institutional
and operator effects are comparable in scope to important differences in
patient presentation in terms of the likelihood that ultra-low contrast vol-
ume would be administered.
4 | DISCUSSION
The key finding of our study is that the use of ultra-low volume con-
trast is increasingly being adopted in the broader interventional com-
munity and is associated with a meaningful reduction in the risk of
TABLE 1 (Continued)
Contrast volume group
Ultra-low contrast
volume compared to
low contrast volume
Ultra-low contrast
volume compared to
high contrast volume
Characteristic
Ultra-low
(CV/CC ≤ 1) Low (CV/CC > 1–3) High (CV/CC > 3) P
Abs.
Std. diff P
Abs.
Std. diff
Stent thrombosis 13/9857 (0.1%) 81/51580 (0.2%) 20/13952 (0.1%) 0.5583 0.7 0.8149 0.3
Postprocedure creatinine 0.87  0.35 1.02  0.44 1.37  0.91 <0.001 36.85 <0.001 73.0
Postprocedure
hemoglobin
12.90  1.84 12.52  1.91 11.34  2.11 <0.001 20.47 <0.001 78.6
Myocardial infarction
(biomarker positive)
107/9849 (1.1%) 906/51557 (1.8%) 403/13945 (2.9%) <0.001 5.67 <0.001 12.9
Cardiogenic shock 73/9850 (0.7%) 790/51557 (1.5%) 618/13946 (4.4%) <0.001 7.47 <0.001 23.4
Heart failure 147/9850 (1.5%) 1384/51558 (2.7%) 925/13946 (6.6%) <0.001 8.34 <0.001 26.3
CVA/stroke 11/9850 (0.1%) 150/51559 (0.3%) 120/13945 (0.9%) 0.001 4.00 <0.001 10.8
Tamponade 5/9850 (0.1%) 42/51557 (0.1%) 45/13945 (0.3%) 0.313 1.19 <0.001 6.3
AKI 145/9857 (1.47%) 1172/51584
(2.27%)
1073/13952
(7.69%)
<0.001 5.91 <0.001 30.1
New requirement for
dialysis
9/9850 (0.1%) 113/51559 (0.2%) 189/13945 (1.4%) 0.009 3.25 <0.001 15.0
Other vascular
complications requiring
treatment
34/9850 (0.3%) 219/51559 (0.4%) 119/13945 (0.9%) 0.259 1.29 <0.001 6.6
RBC/whole blood
transfusion
86/9849 (0.9%) 801/51558 (1.6%) 784/13945 (5.6%) <0.001 6.22 <0.001 27.0
Bleeding event w/in 72 hr 193/9850 (2.0%) 1816/51558 (3.5%) 1173/13946 (8.4%) <0.001 9.58 <0.001 29.4
Discharge status: alive 9821/9857 (99.6%) 51 174/51584
(99.2%)
13 457/13952
(96.5%)
<0.001 5.66 <0.001 23.1
Discharge status:
deceased
36/9857 (0.4%) 410/51584 (0.8%) 495/13952 (3.5%) <0.001 5.66 <0.001 23.1
FIGURE 2 Unadjusted and risk adjusted incidence of AKI by
categories of contrast volume/CC
FIGURE 3 Risk adjusted AKI rates by CV/CC categories and
preprocedural predicted risk of AKI
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AKI among high-risk patients. The use of CV/CC ratio is a simple tool
that may be helpful in guiding contrast dosing in patients undergoing
PCI. In our previous work, the risk of AKI and need for dialysis was
markedly increased when the CV/CC ratio exceeded 3. Our findings
corroborate and significantly extend the findings by focusing on the
other end of the spectrum of contrast use and demonstrate significant
improvement in outcome with use of ultra-low volume contrast espe-
cially in high-risk patients. Because CC is routinely calculated for
patients undergoing invasive cardiac procedures, and the use of
CV/CC ratio is increasingly being incorporated into clinical practice,
clinical adoption of our current findings should be relatively
straightforward.
The morbidity and health care cost associated with CI-AKI has
been described by many investigators 1. Both in vivo data and clinical
studies have demonstrated an association between high contrast vol-
ume and the risk of AKI 20,21. Various different contrast thresholds
have been described and collaborative efforts to reduce the propor-
tion of patients exceeding these thresholds have been associated with
a reduction in the incidence of AKI 22–24. In a recent study, we
described the trends in contrast use over a 7-year period in Michigan
8. There was a steady decline in the average contrast volume per pro-
cedure over the study period with the mean contrast volume declining
from 197 (75) mL in calendar year 2010 to 168 (75) mL in calendar
year 2016. There was a substantial decline in the proportion of
patients exceeding CV/CC ≥ 3 with a commensurate reduction in the
risk adjusted incidence of AKI.
Although these efforts have focused on avoiding high volumes of
contrast media, many groups have focused on performing PCI with
exceedingly low volume of contrast. One of the earliest such report
was from Kane and colleagues who described their experience with
ultra-low volume of contrast use in a cohort of 185 patients with
National Kidney Foundation stages 3–5 chronic, nondialysis-
dependent kidney disease treated at the Mayo clinic. This study dem-
onstrated both the feasibility of such an approach in a larger cohort
and the associated reduction in the incidence of AKI with use of lower
volumes of contrast media 9. An approach for minimizing contrast vol-
ume to less than 15 mL was reported by Nayak and colleagues who
described their strategy of routine biplane angiography, use of adjunc-
tive imaging such as intravascular ultrasound (IVUS) guidance, “dry”
fluoroscopic imaging, and careful minimization of the contrast injec-
tion in the highest-risk patients 10. These benefits of using IVUS guid-
ance to minimize contrast media volume have been further validated
in a randomized trial by Mariani and colleagues. 25. This field has been
further extended by the pioneering work of Ali and colleagues who
have reported on a series of patients on whom they were able to per-
form PCI without using any contrast media whatsoever 26. More
recently, studies of the Dyevert system (Osprey Medical Inc., Minne-
tonka, MN) have demonstrated clinically and statistically significant
reductions in the volume of contrast media administered during coro-
nary angiography and/or interventions 27,28.
These studies reflect the experience of select quaternary care
institutions and the broad uptake of these approaches in the broader
community has previously not been explored. Our work suggests that
a select group of operators across multiple hospitals are adopting the
principle of ultra-low volume contrast. Paradoxically, a majority of
patients who were treated with low volume contrast were at low risk
of AKI and this may simply reflect the adoption of an “As low as rea-
sonably achievable (ALARA)” approach to contrast dosing. More impor-
tantly, the use of ultra-low contrast media was associated with
meaningful reduction in the incidence of AKI in high-risk patients.
Whereas association cannot be used to ascribe causality, the observed
differences in the incidence of AKI with use of ultra-low contrast vol-
ume suggest that broader adoption of this approach needs to be
explored.
FIGURE 4 Use of ultra-low volume contrast as a proportion of all cases performed by an operator or at a participating institution in Michigan
[Color figure can be viewed at wileyonlinelibrary.com]
228 GURM ET AL.
A key finding of our study was that the strongest predictor of
ultra-low contrast volume was the operator and to a lesser extent the
institution performing the procedure. This suggests that there may be
opportunities to both selectively refer high-risk patients to operators
and institutions that are more likely to use ultra-low volume of con-
trast as well as to train operators more broadly on the principles of
ultra-low volume contrast use. Furthermore, we believe, that such
metrics should be, in general, shared with high-risk patients undergo-
ing nonemergent PCI as part of better informed consent process.
The highest-risk patients make up 12.5% of the total population
undergoing PCI in our cohort and had 63.4% of the total CI-AKI
events. Future quality improvement efforts focused on broader utili-
zation of ultra-low volume contrast in this population are needed to
assess if this approach will result in reduced morbidity and health
care cost.
4.1 | Study limitations
The BMC2-PCI registry is a regional database from the state of Michi-
gan with an active focus on multicentric quality improvement and
might or might not be representative of the wider population of
patients undergoing PCI. The collaborative has been focused on use
of renal function-based contrast thresholds and this metric is tracked
quarterly by all participating hospitals. Our findings however reflect
the work across the entire state of Michigan and comprise the experi-
ence of both academic and community hospitals and make our find-
ings more generalizable. Data were limited to in-hospital information,
serum creatinine was not collected in a standardized fashion, and only
the highest post-PCI value was recorded. It is likely that a number of
patients were discharged before peaking of the serum creatinine, and
our study might underestimate the occurrence of AKI. Our study is
observational in nature and cannot ascribe causality.
5 | CONCLUSION
A small but significant proportion of patients undergoing PCI are trea-
ted with ultra-low volume of contrast. The use of ultra-low volume of
contrast is associated with a reduction in the risk of AKI especially in
the highest-risk patients. Further studies are warranted to explore
broader utilization of this threshold in high-risk patients
undergoing PCI.
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